News Sentiment

CMRX sentiment intelligence

Chimerix Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 45 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 8.54 Week of 19 Jun 2026
Weighted tone 55/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Deals and strategy

71/100 classification confidence.

Company focus 38

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend active

+0.0% over one week, +0.0% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Glioblastoma Multiforme Market to Witness Transformational Growth Opportunities by 2036 – DelveInsight | AstraZeneca, DNAtrix, Chimerix, Northwest Therapeutics, Bayer, Kazia Therapeutics, Aivita Bio

Market Reaction

Balanced read

51/100 confidence

News tone and price action are not far from neutral.

Primary event Deals and strategy 71/100 classification
One-week reaction 0.0% Price digesting
Trend fit Trend active 0.0% over four weeks
Fair value 213.4% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 12
Neutral 28
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 38
Industry context 7
Sector context 0

Sources

Coverage mix

Publishers
Market source 5
Stock Titan 4
GlobeNewswire 3
CoinCodex 3
simplywall.st 2
Meyka 2
Insider Monkey 2
PR Newswire 2

Event Lens

What the news is about

Classified themes
Earnings 14
Deals and strategy 14
Market update 12
Regulatory and legal 2
Macro sensitivity 1
Capital return 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 45
Barchart.com Direct company coverage

Glioblastoma Multiforme Market to Witness Transformational Growth Opportunities by 2036 – DelveInsight | AstraZeneca, DNAtrix, Chimerix, Northwest Therapeutics, Bayer, Kazia Therapeutics, Aivita Bio

The Glioblastoma Multiforme (GBM) market is predicted to grow significantly, from approximately USD 900 million in 2025 to nearly USD 4.8 billion by 2036, driven by an increasing prevalence of the disease and advancements in therapeutic pipelines. Key companies like AstraZeneca,

Tone
Neutral 50/100
Event
Market update
Published
27 May 2026 04:40
Source
Barchart.com
StocksToTrade Direct company coverage

Chimerix Inc. (CMRX) Stock Price | Live Quotes & Charts | NASDAQ

The NASDAQ page for Chimerix Inc. (CMRX) provides current stock price information, showing it is trading at $8.54 with no change. The article notes that there are no analyst ratings or earnings information currently available for the company. It also promotes joining an options t

Tone
Neutral 50/100
Event
Earnings
Published
13 May 2026 01:09
Source
StocksToTrade
FX News Group Direct company coverage

SEC announces settled order for insider trading charges related to Chimerix acquisition

The SEC has announced a settled order against Weizheng Zeng for insider trading related to Jazz Pharmaceuticals' acquisition of Chimerix. Zeng, who was involved in the due diligence for the transaction at Jazz, purchased Chimerix stock based on material nonpublic information, res

Tone
Negative 19/100
Event
Deals and strategy
Published
20 Apr 2026 16:08
Source
FX News Group
Meyka Direct company coverage

CMRX Stock Price $8.54 | Chimerix, Inc. Live Quote

This article provides an overview of Chimerix, Inc. (CMRX) stock, detailing its current price, market capitalization, and key financial metrics like P/E ratio and EPS. It highlights an AI-powered analysis with a "B" score, indicating moderate investment characteristics, and provi

Tone
Neutral 50/100
Event
Earnings
Published
02 Apr 2026 17:09
Source
Meyka
Meyka Direct company coverage

CMRX $8.54 intraday (Chimerix, Inc., NASDAQ) 12 Mar 2026: watch $6.67 support

Chimerix Inc. (CMRX) is trading at $8.54 intraday on NASDAQ, presenting a potential oversold bounce opportunity with key support levels at the 50-day average of $6.67 and the 200-day average of $2.75. Meyka AI rates CMRX with a score of 67 (Grade B, HOLD suggestion), projecting a

Tone
Neutral 50/100
Event
Macro sensitivity
Published
12 Mar 2026 20:52
Source
Meyka
AD HOC NEWS Direct company coverage

Chimerix Shares Approach Peak on Partner’s Rosy Forecast

Chimerix Inc. shares are nearing their 52-week high, driven by a rosy financial forecast from its Japanese partner, SymBio Pharmaceuticals. SymBio projects a dramatic 197.5% increase in revenue for the 2026 fiscal year, primarily attributed to brincidofovir (SyB V-1901), suggesti

Tone
Neutral 50/100
Event
Earnings
Published
07 Feb 2026 22:28
Source
AD HOC NEWS
Finansavisen Direct company coverage

Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer

Jazz Pharmaceuticals plc announced the appointment of Thomas Riga as Chief Business Officer, effective January 1, 2026. Mr. Riga brings over 25 years of commercial and operational experience, having previously served as chief operating and commercial officer at Chimerix Inc., whe

Tone
Neutral 50/100
Event
Market update
Published
08 Jan 2026 22:05
Source
Finansavisen
GlobeNewswire Direct company coverage

Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch

Immix Biopharma has appointed Michael Grabow as Chief Commercial Officer to lead the U.S. launch and commercialization of NXC-201, a therapeutic for relapsed/refractory AL Amyloidosis. Grabow previously led the Go-To-Market Strategy and Launch for MODEYSO® at Chimerix, a company

Tone
Positive 62/100
Event
Market update
Published
12 Nov 2025 08:45
Source
GlobeNewswire
BioCentury Direct company coverage

Former Chimerix CEO Andriole to lead Artios

Michael Andriole, former CEO of Chimerix, has been appointed as the new CEO of Artios Pharma Ltd., succeeding Niall Martin. Andriole's appointment follows Chimerix's acquisition by Jazz Pharmaceuticals earlier this year. Additionally, Sam Whiting has joined Vividion Therapeutics

Tone
Neutral 50/100
Event
Deals and strategy
Published
14 Aug 2025 12:46
Source
BioCentury
MarketBeat Direct company coverage

Chimerix (CMRX) FDA Approvals, PDUFA Dates & Drug Alerts 2026

This article details the FDA approval process for Chimerix's (CMRX) drug, dordaviprone, which is a treatment for recurrent H3 K27M-mutant diffuse glioma. It outlines a timeline of regulatory milestones, including the drug's FDA accelerated approval on August 6, 2025, NCCN recomme

Tone
Neutral 50/100
Event
Regulatory and legal
Published
09 Jul 2025 04:39
Source
MarketBeat
Insider Monkey Direct company coverage

Why Chimerix Inc. (CMRX) is Surging in 2025

Chimerix Inc. (NASDAQ:CMRX) is experiencing a significant surge in 2025, driven primarily by the FDA's acceptance of its New Drug Application for dordaviprone with Priority Review and, more significantly, an acquisition announcement by Jazz Pharmaceuticals for $8.55 per share. Th

Tone
Positive 72/100
Event
Deals and strategy
Published
30 Apr 2025 05:46
Source
Insider Monkey
Stock Titan Direct company coverage

CMRX Stock Price, News & Analysis

Chimerix (NASDAQ: CMRX) is a biopharmaceutical company focused on developing therapies for deadly diseases, particularly H3 K27M-mutant diffuse glioma with its lead program dordaviprone (ONC201). The company has submitted an NDA for dordaviprone, which has Priority Review and a P

Tone
Positive 72/100
Event
Market update
Published
24 Apr 2025 16:51
Source
Stock Titan
Contract Pharma Direct company coverage

Jazz Pharmaceuticals Acquires Chimerix for $935M

Jazz Pharmaceuticals has completed its acquisition of Chimerix Inc. for approximately $935 million, integrating Chimerix as a wholly owned subsidiary. This acquisition adds dordaviprone, a novel treatment in development for H3 K27M-mutant diffuse glioma, to Jazz's oncology portfo

Tone
Positive 70/100
Event
Deals and strategy
Published
22 Apr 2025 19:21
Source
Contract Pharma
TipRanks Direct company coverage

Chimerix Terminates Loan and Delists from Nasdaq

Chimerix (CMRX) has terminated its loan agreement with Silicon Valley Bank and requested delisting from Nasdaq following a merger where it became a wholly-owned subsidiary of a parent company. Despite facing significant financial challenges like declining revenues and persistent

Tone
Negative 29/100
Event
Deals and strategy
Published
21 Apr 2025 18:52
Source
TipRanks
Fierce Biotech Direct company coverage

Chimerix engaged with 7 other biopharmas before choosing Jazz's $935M deal—here's why it won

Chimerix considered offers from seven other biopharmas before accepting Jazz Pharmaceuticals' $935 million acquisition deal. The company's board favored Jazz's all-cash offer due to its immediate value for stockholders, the bearish financial climate in biopharma, and general mark

Tone
Positive 73/100
Event
Deals and strategy
Published
21 Mar 2025 17:17
Source
Fierce Biotech
qz.com Direct company coverage

Chimerix Inc. (CMRX) reports earnings

Chimerix Inc. (CMRX) reported a net loss of $88.4 million for the fiscal year ended December 31, 2024, with total revenues of $0.2 million. The company is focusing on its lead product candidate, dordaviprone, and recently entered into a merger agreement with Jazz Pharmaceuticals,

Tone
Positive 71/100
Event
Deals and strategy
Published
21 Mar 2025 00:00
Source
qz.com
MedCity News Direct company coverage

First-in-Class Brain Cancer Drug Strikes a Chord With Jazz Pharma to the Tune of a $935M M&A Deal

Jazz Pharmaceuticals is set to acquire Chimerix for $935 million, primarily for dordaviprone, a first-in-class brain cancer drug targeting H3 K27M-mutant diffuse glioma. This acquisition aims to address a significant unmet medical need for a rare and aggressive form of brain canc

Tone
Positive 92/100
Event
Deals and strategy
Published
06 Mar 2025 20:40
Source
MedCity News
Oncology Pipeline Direct company coverage

Chimerix turns $39m into $935m | ApexOnco - Clinical Trials news and analysis

Jazz Pharmaceuticals acquired Chimerix for $935 million, primarily for its lead asset dordaviprone, which Chimerix had acquired through Oncoceutics for just $78 million. This acquisition represents a success for Chimerix, particularly given the struggles of its previous lead proj

Tone
Positive 71/100
Event
Deals and strategy
Published
05 Mar 2025 22:09
Source
Oncology Pipeline
GlobeNewswire Direct company coverage

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of

Brodsky & Smith is reminding investors about ongoing investigations into the acquisitions of Chimerix, Inc. (CMRX), Siyata Mobile Inc. (SYTA), Bridge Investment Group Holdings Inc. (BRDG), and Intevac, Inc. (IVAC). The law firm is investigating whether the boards of these compani

Tone
Neutral 50/100
Event
Deals and strategy
Published
05 Mar 2025 12:27
Source
GlobeNewswire